Table 2 Clinical and pathological data summaries in both training, validation and testing cohort.
| Â | Training group | Validation group | Testing group | P value |
|---|---|---|---|---|
(N = 123) | (N = 29) | (N = 49) | ||
Age (years) | 45.74 ± 15.51 | 46.86 ± 11.22 | 47.04 ± 13.93 | 0.961 |
  < 30 | 25 (20.3%) | 5 (17.2%) | 8 (16.3%) |  |
 30–50 | 45 (36.6%) | 11 (37.9%) | 20 (40.8%) |  |
  > 50 | 53 (43.1%) | 13 (44.9%) | 21 (42.9%) |  |
Ki-67 expression (%) | 25.19 ± 24.30 | 32.25 ± 31.85 | 30.09 ± 27.67 | 0.946 |
  < 50 | 85 (78.0%) | 17 (70.8%) | 31 (68.9%) |  |
 50–75 | 19 (17.4%) | 4 (16.7%) | 9 (20.0%) |  |
  > 75 | 5 (4.6%) | 3 (12.5%) | 5 (11.1%) |  |
CA-125 level(IU/L) | 514.41 ± 887.01 | 363.24 ± 375.51 | 370.87 ± 565.14 | 0.956 |
  < 35 | 15 (18.3%) | 5 (29.4%) | 10 (30.3%) |  |
 35–200 | 28 (34.1%) | 4 (23.5%) | 8 (24.2%) |  |
 200–500 | 16 (19.5%) | 2 (11.8%) | 7 (21.3%) |  |
  > 500 | 23 (28.1%) | 6 (35.3%) | 8 (24.2%) |  |
Category | Â | Â | Â | 0.980 |
 Borderline tumor | 62 (50.4%) | 15 (51.7%) | 25 (51.0%) |  |
 Malignancies | 61 (49.6%) | 14 (48.3%) | 24 (49.0%) |  |
 Endometroid cancer | 3 (4.9%) | 1 (7.1%) | 2 (8.3%) |  |
 Low-grade adenocarcinoma | 9 (14.7%) | 4 (28.7%) | 5 (20.8%) |  |
 Clear cell type | 4 (6.6%) | 1 (7.1%) | 3 (12.5%) |  |
 High-grade Serous carcinoma | 45 (73.8%) | 7 (50.0%) | 14 (58.4%) |  |
 Mixed carcinoma | 0 (0%) | 1 (7.1%) | 0 (0%) |  |
